Intavis Peptide Services

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐏𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐏𝐄𝐓 𝐭𝐫𝐚𝐜𝐞𝐫 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐋𝐀𝐆-­𝟑 𝐟𝐨𝐫 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐨𝐟 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐦𝐞𝐥𝐚𝐧𝐨𝐦𝐚" The authors develop and evaluate a novel peptide-based positron emission tomography (PET) tracer, 68Ga-NOTA-XH05, which targets Lymphocyte Activation Gene-3 (LAG-3) for non-invasive imaging. The purpose of this tracer is to monitor LAG-3 expression in melanoma tumors to assess the efficacy of immunotherapy treatments, specifically CpG oligonucleotide (CpG) therapy. The study demonstrates that 68Ga-NOTA-XH05 can accurately reflect LAG-3 expression levels in tumors and differentiate between responders and non-responders to immunotherapy. This PET tracer shows potential as a valuable tool for evaluating the immune response in tumors and could aid in clinical decision-making for cancer immunotherapy. In the growing field of radio ligand cancer therapy, peptides are proving do be very versatile tools. Either as tracers or as vehicles to transport isotopes to the cancer, scientists have grown the peptide toolbox tremendously, opening new avenues for improving cancer treatment. Paper reference: Yuan, P., Long, Y., Wei, N., Wang, Y., Zhu, Z., Han, J., ... & Gai, Y. (2024). Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma. Journal for Immunotherapy of Cancer, 12(7). #PeptideTherapy #CancerResearch #Immunotherapy #radioligand

The first house of Intavis Peptide Services is located in the 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐚𝐫𝐤 𝐓ü𝐛𝐢𝐧𝐠𝐞𝐧-𝐑𝐞𝐮𝐭𝐥𝐢𝐧𝐠𝐞𝐧 (𝐓𝐓𝐑). This location is unique because there are over 100 companies in this area. The 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐚𝐫𝐤 𝐓ü𝐛𝐢𝐧𝐠𝐞𝐧-𝐑𝐞𝐮𝐭𝐥𝐢𝐧𝐠𝐞𝐧 (𝐓𝐓𝐑) is a well-organized business and research area located in the southwest of Germany. Its purpose is fostering innovation and collaboration in fields such as life sciences, information technology, and engineering. The park has a suburban and business-focused flair but is also surrounded by green spaces, which add a pleasant atmosphere. This is a place where scientists can focus, contemplate and do research. You can observe an aerial view of these areas in the image below. #TechnologyPark #IntavisPeptide #Tübingen #Reutlingen

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 We're conducting a quick poll to gather insights on key factors influencing immune response in neoantigen vaccines. Your expertise is invaluable—please share your thoughts on which peptide characteristic you believe is most crucial for a robust immune response. #NeoantigenVaccines #Immunology #peptides

We look forward to meeting you in 𝐅𝐥𝐨𝐫𝐞𝐧𝐜𝐞, 𝐈𝐭𝐚𝐥𝐲, 𝐚𝐭 𝐭𝐡𝐞 𝟑𝟕𝐭𝐡 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦, August 25-28. Our Chief Scientific Officer, Felix Niethammer, will be there to discuss your peptide projects Check out Intavis Peptide Services website in the comment to learn more about us. #peptides #biotechnology #peptidesynthesis #SPPS #drugdevelopment #innovation #chemistry #structuralbiology #𝐄𝐏𝐒𝟐𝟎𝟐𝟒

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐈𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐳𝐞𝐝 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐢𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐜 𝐜𝐚𝐧𝐜𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭: 𝐚 𝐜𝐚𝐬𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐨𝐟 𝐜𝐨𝐦𝐛𝐢𝐧𝐞𝐝 𝐭𝐮𝐦𝐨𝐫 𝐚𝐧𝐝 𝐥𝐢𝐪𝐮𝐢𝐝 𝐛𝐢𝐨𝐩𝐬𝐲" The authors report on a case of metastatic pancreatic cancer treated with 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐳𝐞𝐝 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐢𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 combined with standard chemotherapy, resulting in significant tumor marker reduction, tumor shrinkage, and improved patient quality of life without severe side effects. The study demonstrates the potential of personalized immunotherapy in enhancing treatment efficacy and patient well-being in advanced pancreatic cancer. 𝐖𝐡𝐚𝐭 𝐦𝐞𝐭𝐡𝐨𝐝𝐬 𝐰𝐞𝐫𝐞 𝐮𝐬𝐞𝐝 𝐭𝐨 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐚𝐧𝐝 𝐚𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐞𝐫 𝐭𝐡𝐞 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭'𝐬 𝐢𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐲? The methods for identifying and administering the neoantigen peptides involved extracting genomic DNA and RNA from the patient's tumor tissue, as well as cell-free DNA from blood samples, followed by next-generation sequencing to identify somatic mutations. Computational prediction techniques were then used to identify immunogenic epitopes, which were synthesized into peptides. These peptides, combined with the adjuvant Montanide ISA 51 VG, were administered subcutaneously in multiple locations, alongside nivolumab and imiquimod to enhance the immune response. The patient received a series of five biweekly prime injections followed by two booster injections, integrated with standard chemotherapy, to target the tumor effectively. "𝐈𝐟 𝐲𝐨𝐮 𝐧𝐞𝐞𝐝 𝐚 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞 𝐚𝐧𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐝 𝐩𝐚𝐫𝐭𝐧𝐞𝐫 𝐭𝐨 𝐩𝐫𝐨𝐯𝐢𝐝𝐞 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐜𝐡𝐞𝐜𝐤 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭." Paper & picture reference: Roehnisch, T., Martos-Contreras, M. C., Manoochehri, M., Nogueira, M., Bremm, F., Dörrie, J., ... & Schönharting, W. (2024). Individualized neoantigen peptide immunization of a metastatic pancreatic cancer patient: a case report of combined tumor and liquid biopsy. Frontiers in Immunology, 15, 1414737. #NeoantigenTherapy #PeptideVaccine #PancreaticCancer #Peptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐓𝐡𝐞 𝐧𝐞𝐜𝐞𝐬𝐬𝐚𝐫𝐲 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐚𝐧 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐭𝐮𝐦𝐨𝐫 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐛𝐲 𝐌𝐇𝐂 𝐈𝐈 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐨𝐧 𝐚𝐦𝐚𝐭𝐞𝐮𝐫 𝐀𝐏𝐂" The authors explores the critical role of major histocompatibility complex class II (MHC II) expression on amateur antigen-presenting cells (aAPCs) in enhancing tumor immunotherapy by effectively activating CD4+ helper T cells, addressing the limitations of traditional professional APCs. 𝐇𝐨𝐰 𝐝𝐨 𝐚𝐦𝐚𝐭𝐞𝐮𝐫 𝐀𝐏𝐂𝐬 (𝐚𝐀𝐏𝐂𝐬) 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐞 𝐭𝐨 𝐢𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐩𝐚𝐩𝐞𝐫? Antigen-presenting cells (APCs) are crucial in initiating and regulating the immune response by capturing, processing, and presenting antigens to T cells, with professional APCs (pAPCs) such as dendritic cells, macrophages, and B cells being the most efficient. However, amateur APCs (aAPCs), including cancer cells, fibroblasts, vascular endothelial cells (VECs), and lymphoid stromal cells (LSCs), also express MHC II molecules and can present antigens. The authors highlight that aAPCs can enhance the efficacy of cancer immunotherapy by increasing antigen presentation and activating CD4+ helper T cells, which are essential for a robust immune response. This increased presentation supports the activation of CD8+ cytotoxic T cells, leading to more effective tumor cell killing. Additionally, the expression of MHC II on aAPCs can serve as a biomarker to predict patient response to immunotherapies, allowing for more tailored and potentially effective treatments. This research suggests that targeting MHC II on non-classical APCs, such as cancer cells, fibroblasts, and vascular endothelial cells, could serve as a promising strategy to improve the efficacy of cancer immunotherapy and guide therapeutic interventions. Specifically, when designing peptide vaccines, it could be advisable to target both, MHC class I and II for inducing a stronger immune response. Paper reference: Zhong, J., Lin, X., & Hu, H. (2024). The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs. Malignancy Spectrum. #CancerResearch #Immunotherapy #peptides #IntavisResearchRoundUp

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐍𝐞𝐰𝐬 "𝐓𝐡𝐞 𝐑𝐨𝐥𝐞 𝐚𝐧𝐝 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐨𝐟 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐢𝐧 𝐂𝐞𝐫𝐯𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭" The authors examine the development and effectiveness of peptide vaccines targeting HPV oncoproteins E6 and E7 in treating cervical cancer. These vaccines are advantageous due to their 𝐡𝐢𝐠𝐡 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐢𝐭𝐲, 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐚𝐧𝐝 𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐭𝐨 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐬𝐭𝐫𝐨𝐧𝐠, 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐢𝐦𝐦𝐮𝐧𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞𝐬 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐞𝐥𝐥𝐬. They also discuss the progress made in clinical trials, the role of adjuvants in enhancing vaccine efficacy, and the challenges that need to be overcome, such as individual variability in immune responses and the need for effective delivery systems. This highlights the role that 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬 can play in research focused on the prevention of infectious diseases and cancer treatment. 𝐀𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬 𝐨𝐟 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐇𝐏𝐕 𝐎𝐧𝐜𝐨𝐩𝐫𝐨𝐭𝐞𝐢𝐧𝐬: 𝐇𝐢𝐠𝐡 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐢𝐭𝐲: These vaccines are designed to target specific antigenic peptides from HPV oncoproteins E6 and E7, ensuring that the immune response is directed precisely at cancer cells harboring these proteins. 𝐒𝐚𝐟𝐞𝐭𝐲: Peptide vaccines are generally safe, as they are fully synthetic and do not carry the risk of virulence reversion or infection associated with live or attenuated vaccines. 𝐒𝐭𝐫𝐨𝐧𝐠 𝐈𝐦𝐦𝐮𝐧𝐞 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞: They can elicit robust cellular immune responses, particularly by activating CD4+ helper T cells and CD8+ cytotoxic T cells, which are crucial for attacking and eliminating HPV-infected cancer cells. 𝐌𝐢𝐧𝐢𝐦𝐚𝐥 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲: Unlike traditional cancer treatments such as chemotherapy and radiotherapy, peptide vaccines typically have lower toxicity and fewer side effects, improving patient quality of life during treatment. Paper reference: Wang, M., Gong, Y., Kang, W., Liu, X., & Liang, X. (2024). The Role and Development of Peptide Vaccines in Cervical Cancer Treatment. International Journal of Peptide Research and Therapeutics, 30(4), 40. #PeptideVaccines #CervicalCancer #HPVResearch #peptides

𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐭𝐚𝐢𝐥𝐨𝐫𝐞𝐝 𝐭𝐨 𝐲𝐨𝐮𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡, 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐝 𝐰𝐢𝐭𝐡 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 At Intavis Peptide Services , we specialize in providing 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 tailored to meet the specific needs of your research. 𝐎𝐮𝐫 𝐜𝐨𝐦𝐦𝐢𝐭𝐦𝐞𝐧𝐭 𝐭𝐨 𝐞𝐱𝐜𝐞𝐥𝐥𝐞𝐧𝐜𝐞 𝐢𝐧 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 ensures that every peptide we produce is of the highest standard, supporting scientists and researchers in achieving accurate and reliable results. With 𝟑𝟎 𝐲𝐞𝐚𝐫𝐬 𝐨𝐟 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 and a team of respected experts, we are proud to announce that we will soon offer 𝐆𝐌𝐏 𝐚𝐧𝐝 𝐧𝐞𝐨𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐯𝐚𝐜𝐜𝐢𝐧𝐞𝐬. Visit our website at 𝐢𝐧𝐭𝐚𝐯𝐢𝐬𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬.𝐜𝐨𝐦 to learn more about how we can enhance your research with our expertly crafted peptides. Check our website in the comment. #IntavisPeptides #GMPPeptides #NeoantigenVaccines #Peptides

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐖𝐞𝐞𝐤𝐥𝐲 𝐏𝐨𝐥𝐥 Neoantigens play a crucial role in cancer immunotherapy. In tumors with high mutational burden, which mutational event is most likely to generate neoantigens? 𝐏𝐥𝐞𝐚𝐬𝐞 𝐬𝐡𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬! #CancerResearch #Neoantigens #Oncology

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐌𝐞𝐭𝐡𝐨𝐝𝐬 𝐟𝐨𝐫 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐚𝐧𝐝 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐥𝐢𝐛𝐫𝐚𝐫𝐢𝐞𝐬 𝐨𝐟 𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐞𝐧𝐜𝐨𝐝𝐞𝐝 𝐜𝐲𝐜𝐥𝐢𝐜 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲" 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐩𝐡𝐚𝐠𝐞 𝐝𝐢𝐬𝐩𝐥𝐚𝐲 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐞 𝐮𝐬𝐞𝐝 𝐭𝐨 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲 𝐡𝐢𝐠𝐡-𝐚𝐟𝐟𝐢𝐧𝐢𝐭𝐲 𝐜𝐲𝐜𝐥𝐢𝐜 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬, 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐭𝐡𝐨𝐝 𝐨𝐟𝐟𝐞𝐫 𝐟𝐨𝐫 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲? Phage display technology can be used to identify high-affinity cyclic peptide inhibitors by displaying a vast library of cyclic peptides on the surface of bacteriophages. These peptides are screened against a target protein to select those with the highest binding affinity. The advantages of this method for drug discovery include the availability of commercial kits, the ability to chemically modify peptides for enhanced stability, and the robust selection of peptides with high target specificity and affinity. This technology facilitates the rapid identification of potential therapeutic agents, making it a valuable tool for advancing drug discovery and development, as supported by services provided at 𝐢𝐧𝐭𝐚𝐯𝐢𝐬𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬.𝐜𝐨𝐦 Paper reference: Sohrabi, C., Foster, A., & Tavassoli, A. (2020). Methods for generating and screening libraries of genetically encoded cyclic peptides in drug discovery. Nature Reviews Chemistry, 4(2), 90-101. #CyclicPeptides #DrugDiscovery #Peptides